Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 3/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4740697 | 1.00 | KMT2A (0.41) | KMT2APPARDF2F10PKM | |
| SCHEMBL1471222 | 1.00 | KMT2A (0.41) | KMT2APPARDF2F10PKM | |
| SCHEMBL4916166 | 0.86 | CA1 (0.43) | KMT2APPARDF2F10PKM | |
| SCHEMBL14538800 | 0.83 | KMT2A (0.39) | KMT2APPARDF2F10PKM | |
| SCHEMBL2073043 | 0.82 | PPARD (0.46) | KMT2APPARDF2F10MAPT | |
| SCHEMBL2073041 | 0.82 | PPARD (0.46) | KMT2APPARDF2F10MAPT | |
| SCHEMBL2073038 | 0.82 | PPARD (0.46) | KMT2APPARDF2F10MAPT | |
| SCHEMBL1339793 | 0.81 | KMT2A (0.46) | KMT2AF2F10PKMMTNR1A | |
| SCHEMBL4915544 | 0.78 | KMT2A (0.35) | KMT2APPARDF2F10ALDH1A1 | |
| SCHEMBL20308946 | 0.78 | PPARD (0.53) | KMT2APPARDPKMALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1805158-B1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS INC (US) | 2018-06-27 | — | — | EP | disclosed |
| US-9463189-B2 | Sulfonyl-substituted bicyclic compounds as PPAR modulators for the treatment of non-alcoholic steatohepatitis | BPV HOLDINGS, LLC (US) | 2016-10-11 | — | — | US | disclosed |
| US-9463189-B2 | Sulfonyl-substituted bicyclic compounds as PPAR modulators for the treatment of non-alcoholic steatohepatitis | BPV HOLDINGS, LLC (US) | 2016-10-11 | — | — | US | disclosed |
| US-9463189-B2 | Sulfonyl-substituted bicyclic compounds as PPAR modulators for the treatment of non-alcoholic steatohepatitis | BPV HOLDINGS, LLC (US) | 2016-10-11 | — | — | US | disclosed |
| US-20130252970-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS PPAR MODULATORS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | KALYPSYS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252970-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS PPAR MODULATORS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | KALYPSYS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252970-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS PPAR MODULATORS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | KALYPSYS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-7915253-B2 | 4-[2,6-Dimethyl-4-(4-trifluoromethoxy-phenyl)-piperazine-1-sulfonyl]-indan-2-carboxylic acid; peroxisome proliferator activated receptors modulator; antidiabetic, antiinflammatory agent; obesity, hyperinsulinemia, metabolic syndrome X, polycystic ovary syndrome, ischemia-associated organ injury | KALYPSYS, INC (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915253-B2 | 4-[2,6-Dimethyl-4-(4-trifluoromethoxy-phenyl)-piperazine-1-sulfonyl]-indan-2-carboxylic acid; peroxisome proliferator activated receptors modulator; antidiabetic, antiinflammatory agent; obesity, hyperinsulinemia, metabolic syndrome X, polycystic ovary syndrome, ischemia-associated organ injury | KALYPSYS, INC (US) | 2011-03-29 | — | — | US | disclosed |
| US-7863276-B2 | Salts of modulators of PPAR and methods of treating metabolic disorders | KALYPSYS, INC (US) | 2011-01-04 | — | — | US | disclosed |
| US-20070249519-A1 | METHODS FOR THE UPREGULATION OF GLUT4 VIA MODULATION OF PPAR DELTA IN ADIPOSE TISSUE AND FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070249519-A1 | METHODS FOR THE UPREGULATION OF GLUT4 VIA MODULATION OF PPAR DELTA IN ADIPOSE TISSUE AND FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070249519-A1 | METHODS FOR THE UPREGULATION OF GLUT4 VIA MODULATION OF PPAR DELTA IN ADIPOSE TISSUE AND FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2007-10-25 | — | — | US | disclosed |
| EP-1805158-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | Kalypsys, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20070093504-A1 | Salts of Modulators Of PPAR and Methods of Treating Metabolic Disorders | KALYAPSYS, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| US-20070093504-A1 | Salts of Modulators Of PPAR and Methods of Treating Metabolic Disorders | KALYAPSYS, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| WO-2007047432-A1 | SULFONAMIDE DERIVATIVES AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20060205736-A1 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | KALYPSYS, INC. | 2006-09-14 | — | — | US | disclosed |
| US-20060167012-A1 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | KALYPSYS, INC. | 2006-07-27 | — | — | US | disclosed |
| WO-2006055187-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093504-A1 | Salts of Modulators Of PPAR and Methods of Treating Metabolic Disorders | PPARG, PPARA, PPARD | KMT2A 3530/4885PPARD 3/4885F2 3463/4885 |
| US-20060167012-A1 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | PPARG, PPARA, PPARD | KMT2A 3636/4885PPARD 3/4885F2 3981/4885 |
| US-20070249519-A1 | METHODS FOR THE UPREGULATION OF GLUT4 VIA MODULATION OF PPAR DELTA IN ADIPOSE TISSUE AND FOR THE TREATMENT OF DISEASE | FABP4, PPARG, PPARA | KMT2A 4387/4885PPARD 6/4885F2 4859/4885 |
| US-20060205736-A1 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | PPARG, PPARA, PPARD | KMT2A 3636/4885PPARD 3/4885F2 3981/4885 |
| US-20130252970-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS PPAR MODULATORS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | PPARD, PPARG, PPARA | KMT2A 2765/4885PPARD 1/4885F2 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.